HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
LXRX
Lexicon Pharmaceuticals Inc
Healthcare Biotechnology · Texas, USA · Reports in usd
Market Cap: $610.5M
Market Cap
$610.5M
Enterprise Val
$539.3M
P/E Ratio
-12.13
P/B Ratio
5.68
Trailing PEG (1Y)
0.22
As Of
Apr 23, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$107.5M
Gross Margin96.34%
Profit Margin96.34%
Return on Equity-41.94%
Return on Assets-22.03%
Current Ratio4.88
Debt/Equity0.50
LT Debt/Equity0.46
Revenue Per Share0.02

Income Statement

Dec 31, 2025
Revenue$5.5M
Cost of Revenue$201.0K
Gross Profit$5.3M
R&D$11.3M
SG&A$8.8M
Operating Expenses$20.1M
Operating Income-$14.8M
Interest Expense$2.0M
Tax Expense$0.00
Net Income-$15.5M
EPS (Basic)$-0.04
EPS (Diluted)$-0.04
EBIT-$13.5M
EBITDA-$13.4M
Consolidated Income-$15.5M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$63.3M
Accounts Receivable$2.4M
Inventory$281.0K
Current Assets$101.9M
LT Investments$0.00
Property, Plant & Equipment$9.2M
Intangibles$44.5M
Non-Current Assets$83.1M
Total Assets$185.0M
Accounts Payable$3.1M
Current Debt$4.6M
Current Liabilities$20.9M
LT Debt$49.4M
Non-Current Liabilities$56.6M
Total Liabilities$77.4M
Total Debt$54.0M
Retained Earnings-$2.02B
Shareholder Equity$107.5M
Shares Outstanding363,398,680

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$17.2M
Investing Cash Flow$4.8M
Financing Cash Flow-$2.9M
CapEx$0.00
Free Cash Flow-$17.2M
Depreciation & Amort.$118.0K
Stock-Based Comp$2.8M
Acquisitions / Disposals$0.00
Investment Activity$4.8M
Debt Issued/Repaid-$3.0M
Equity Issued/Repaid$73.0K
Dividends Paid$0.00
Net Change in Cash-$15.3M
Data cached · Meta live · Daily live · Statements live · TTL 24h